生物活性

• 描述Dopamine receptors have been associated with many neurological disorders, including most notably Parkinson's disease and schizophrenia. SCH 23390 is a highly potent and selective dopamine D1-like receptor antagonist with a Ki of 0.2 and 0.3 nM for the D1 and D5 dopamine receptor subtypes, respectively. SCH 23390 also binds with high affinity to the 5-HT2 and 5-HT1C serotonin receptor subtypes^[1]. Intra-DLS (dorsolateral striatum) microinfusion of SCH23390 (100 ng) or sulpiride both increased anxiety, indicated by increases in time spent in the enclosed maze arms in rats, while intra-DMS (dorsomedial striatum) microinfusion of SCH23390, sulpiride, or saline did not affect performance in a novelty preference test, indicated by greater time spent in a 'novel' maze arm compared to 'non-novel' arms^[2]. In contextual fear conditioning and memory testing, SCH23390 (0.1 mg/kg) given before conditioning or before both conditioning and retrieval decreased freezing at retrieval, whereas SCH23390 given only before retrieval had no effect. SCH23390 (2.5 μg/0.5 uL) infused into dmPFC (dorsomedial prefrontal cortex) before conditioning decreased freezing at retrieval, while infusion of SCH23390 into NAc (nucleus accumbens) or VH (ventral hippocampus) had no effect^[3].